ATYR aTYR PHARMA INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1339970 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.1%
TTM net income YoY-15.8%
TTM EPS YoY7.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-40,856.3%
Net margin-39,009.5%
FCF margin-32,664.7%
EBITDA margin-40,506.8%
Returns
ROE-107.8%
ROA-78.1%
ROIC (approx.)-106.0%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets27.6%
Debt / equity0.00x
Current ratio5.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-12.8%
Payout ratio—
Capex / revenue40.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | $0 | $190,000 | $0 | $0 | $0 |
| R&D expense | $10.45M | $6.75M | $7.32M | $10.89M | $22.13M | $15.38M | $11.81M | $12.23M |
| SG&A expense | $8.35M | $4.13M | $4.12M | $3.90M | $4.80M | $4.93M | $3.96M | $3.59M |
| Operating income | -$18.79M | -$10.88M | -$11.44M | -$14.80M | -$26.75M | -$20.31M | -$15.77M | -$15.82M |
| Net income | -$18.26M | -$10.31M | -$10.79M | -$13.96M | -$25.74M | -$19.53M | -$14.88M | -$14.97M |
| EBITDA | -$18.62M | -$10.71M | -$11.27M | -$14.63M | -$26.58M | -$20.15M | -$15.61M | -$15.64M |
| EPS (basic) | -7.43 | -0.11 | -0.11 | — | -10.60 | -0.22 | -0.17 | — |
| EPS (diluted) | -7.43 | -0.11 | -0.11 | — | -10.60 | -0.22 | -0.17 | — |
| Weighted avg. shares (diluted) | 2.46M | 98.07M | 98.04M | — | 2.43M | 90.12M | 86.49M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $13.14M | $16.16M | $10.01M | $10.74M | $6.15M | $17.22M | $10.36M | $11.05M |
| Short-term investments | $35.61M | $41.26M | $56.51M | $67.94M | $79.00M | $63.13M | $65.99M | $61.07M |
| Current assets | $50.16M | $58.36M | $67.58M | $80.24M | $93.01M | $87.49M | $83.27M | $81.95M |
| PP&E, net | $3.38M | $4.13M | $4.24M | $4.26M | $4.43M | $4.53M | $4.68M | $4.85M |
| Total assets | $59.81M | $69.83M | $79.65M | $93.00M | $106.65M | $101.53M | $97.25M | $96.83M |
| Current liabilities | $16.46M | $11.40M | $11.70M | $15.15M | $15.68M | $15.53M | $10.68M | $14.97M |
| Total liabilities | $26.01M | $21.23M | $21.91M | $25.71M | $26.61M | $26.88M | $22.38M | $27.00M |
| Shareholders' equity | $33.98M | $48.79M | $57.93M | $67.48M | $80.23M | $74.84M | $75.05M | $70.02M |
| Shares outstanding | 2.51M | 98.09M | 98.05M | 2.45M | 97.99M | 92.87M | 89.00M | 84.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.51M | -$9.35M | -$12.52M | -$12.20M | -$20.48M | -$13.89M | -$15.42M | -$13.13M |
| Capital expenditure | $45,000 | $73,000 | $138,000 | $31,000 | $37,000 | $9,000 | $0 | $25,000 |
| Free cash flow | -$9.56M | -$9.42M | -$12.65M | -$12.23M | -$20.51M | -$13.90M | -$15.42M | -$13.16M |
| Investing cash flow | $5.72M | $15.32M | $11.49M | $16.44M | -$20.38M | $3.30M | -$4.42M | -$6.08M |
| Financing cash flow | $773,000 | -$129,000 | -$142,000 | -$131,000 | $29.62M | $17.90M | $18.63M | $18.84M |
| Depreciation & amortization | $171,000 | $168,000 | $162,000 | $166,000 | $165,000 | $166,000 | $167,000 | $175,000 |
| Stock-based compensation | $2.59M | $1.15M | $1.31M | $1.21M | $1.31M | $1.30M | $1.18M | $770,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.